Pseudouridine derivative

Details Pseudouridine derivative Pseudouridine derivative

1987-12-03

1990-02-27

Griffin, Ronald W.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 187, 536 174, 536 172, C07G 3700, C07H 504, C07H 1500, A01N 4304

Patent

active

049047710

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to a novel pseudouridine derivative that enhances the actions of glucocorticoids. The compound of the present invention is physiologically active in such a way that when used in a very small amount it appreciably enhances the actions of glucocorticoids in physiological concentrations. This compound has the potential to replace steroid drugs, the use of which may cause untoward side effects.


BACKGROUND ART

Glucocorticoids that are steroid hormones secreted from the adrenal cortex and which take part in carbohydrate metabolism are responsible for such phenomena as gluconeogenesis in the liver, promotion of hepatic glycogen storage, and increases in blood glucose levels. It has been desired to develop drugs that reduce or obviate that need to administer steroid drugs, which have strong side effects, by enhancing these actions of glucocorticoids.


DISCLOSURE OF THE INVENTION

The present inventors previously found that substances capable of enhancing the actions of glucocorticoids exist in certain components of enterobacteria. On the basis of this finding, the present inventors undertook investigative work to search for such substances. In the course of this work, the present inventors found that 5'-pseudouridyl-N-oleoyl carbamate represented by the following formula (I) has a very strong glucocorticoid enhancing activity, and the present invention has been accomplished as a result of further studies based on this finding: ##STR2##
The compound of the present invention has a unique structure in that naturally occurring oleic acid and pseudouridine are linked with carbamate. There has been no reported case of using a compound with this chemical structure as a physiologically active substance.
The compound of the present invention is novel and may be prepared by reacting pseudouridine with oleoyl isocyanate in an inert solvent.
The glucocorticoid activity enhancing action of the compound of the present invention was verified by screening on rats with induction of tyrosine aminotransferase, which is the principal activity of glucocorticoids, being used as an index (see the Experiment to be noted below).
The following Experiment and Example are provided for the purpose of further illustrating the present invention but are in no way to be taken as limiting its scope.


EXPERIMENT

The physiological activity of 5'-pseudouridyl-N-oleoyl carbamate was verified by measuring its capability to enhance the ability of glucocorticoids to induce tyrosine aminotransferase (EC 2.6.1.5).
Wistar male rats (weighing 190-220 g) were adrenalectomized 7 or 8 days before the experiment. Thereafter, the animals were fed a laboratory diet and aqueous sodium chloride ad libitum. A solution of 5'-pseudouridyl-N-oleoyl carbamate in physiological saline (containing 10% dimethyl sulfoxide) and/or a solution of glucocorticoid in physiological saline was injected intraperitoneally into the adrenalectomized rats. Five hours later, the rats were slaughtered by twisting their necks. The liver was extracted from each rat and homogenized in six volumes of a 0.25M sucrose buffer solution (50 mM potassium phosphate buffer solution containing 1 mM of 2-oxoglutarate and 48 .mu.M of pyridoxal phosphate; pH, 7.5). The activity of tyrosine aminotranferase in the liver homogenate was measured by the method of Rosen et al. [J. Biol. Chem., 283, 3725-3729 (1963)]. The protein concentration was measured by the method of Lowry et al. [J. Biol. Chem., 173, 265-275 (1951)]. The results are shown in the following table.
The compound of the present invention was found to have the capability to enhance the actions of dexamethasone, hydrocotisone and triamcinolone which are present in limited amounts.


TABLE ______________________________________ Specific activity of tyrosine Treatment aminotransferase (nmol/100 g of body weight) (mU/mg of protein) ______________________________________ Physiological saline 7.0 .+-. 1.1 Compound of the present 7.0 .+-. 1.2 invention (72) Dex* (1) 15.1 .+-.

REFERENCES:
patent: 3935184 (1976-01-01), Jones et al.
patent: 3988314 (1976-10-01), Argoudelis et al.
patent: 4849513 (1989-07-01), Smith et al.
Journal of Heterocyclic Chemistry, vol. 12, No. 4, pp. 817 to 818 (1975).

Affiliated with

Also associated with

Rating

Pseudouridine derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pseudouridine derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pseudouridine derivative will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-175029